Literature DB >> 9034006

Exclusion of linkage between schizophrenia and the gene encoding a neutral amino acid glutamate/aspartate transporter, SLC1A5.

A C Chen1, G Kalsi, J Brynjolfsson, T Sigmundsson, D Curtis, R Butler, T Read, P Murphy, E A Barnard, H Petursson, H M Gurling.   

Abstract

An abnormality in glutamatergic function has been hypothesized as being of etiological importance in schizophrenia. Twenty-three multiplex English and Icelandic schizophrenia families were genotyped with a polymorphic dinucleotide repeat sequence in the 3'-untranslated region of the glutamate/aspartate transporter gene called SLC1A5. Using the lod and a model-free method of linkage analysis (MFLINK), no evidence of linkage between SLC1A5 and schizophrenia was found. Our results do not support the hypothesis that SLC1A5 gene mutations or allelic variants provide a major gene contribution to the etiology of schizophrenia. However, because of the likelihood of heterogeneity of linkage in schizophrenia, there is a case for testing other pedigrees for linkage to the SLC1A5 locus. The SLC1A5 locus is one of a complex family of genes encoding neutral amino acid transporter proteins and the genetic relation between these other loci and schizophrenia has not yet been established.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9034006

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  2 in total

1.  Genome-wide expression profiling in the peripheral blood of patients with fibromyalgia.

Authors:  Kim D Jones; Terri Gelbart; Thomas C Whisenant; Jill Waalen; Tony S Mondala; David N Iklé; Daniel R Salomon; Robert M Bennett; Sunil M Kurian
Journal:  Clin Exp Rheumatol       Date:  2016-02-12       Impact factor: 4.473

2.  Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia.

Authors:  Xiangdong Deng; Noriaki Sagata; Naoko Takeuchi; Masami Tanaka; Hideaki Ninomiya; Nakao Iwata; Norio Ozaki; Hiroki Shibata; Yasuyuki Fukumaki
Journal:  BMC Psychiatry       Date:  2008-07-18       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.